Quantcast

Latest KRAS Stories

2014-12-26 23:00:36

RnRMarketResearch.com adds “Imprime PGG (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.

2014-12-26 23:00:27

RnRMarketResearch.com adds “Vectibix (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.

2014-12-23 23:05:14

RnRMarketResearch.com adds “Zaltrap (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.

2014-11-20 08:34:23

Data presented at the EORTC-NCI-AACR International Symposium Demonstrate High Sensitivity and Strong Quantitative Performance with Trovagene's Precision Cancer Monitoring Platform BARCELONA,

2014-10-30 08:37:13

Presentations at 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology Point to Potential Strategies for Treatment of Small Cell, Non-small Cell, and Neuroendocrine Lung Cancers

2014-09-29 08:30:43

- Median overall survival is encouraging for this patient population - BOULDER, Colo., Sept.

2014-06-30 12:40:20

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.

2014-06-19 12:30:33

Surveyed Payers Are Most Receptive to Therapies Offering a Median Overall Survival Benefit over Available Therapies, According to a New Report from Decision Resources Group BURLINGTON, Mass.,

2014-06-02 12:29:47

Six Phase 3 / Pivotal Trials with Array's MEK Inhibitors Advancing BOULDER, Colo., June 2, 2014 /PRNewswire/ -- Two Array BioPharma-invented MEK inhibitors, binimetinib (MEK162) and


Word of the Day
marcescent
  • Withering but not falling off, as a blossom that persists on a twig after flowering.
The word 'marcescent' comes from a Latin word meaning 'to wither'.
Related